UK markets closed
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.12 +0.12 (+0.15%) GOLD FUTURES
2,311.00 0.00 (0.00%) DOW
38,159.38 +256.09 (+0.68%) Bitcoin GBP
47,126.18 +1,472.98 (+3.23%)
Daiichi Sankyo Company, Limited (4568.T)
Tokyo - Tokyo Delayed price. Currency in JPY
Add to watchlist
At close: 03:15PM JST
| Previous close | 5,335.00 |
| Open | 5,335.00 |
| Bid | 5,489.00 x N/A |
| Ask | 5,503.00 x N/A |
| Day's range | 5,301.00 - 5,520.00 |
| 52-week range | 3,566.00 - 5,520.00 |
| Volume | |
| Avg. volume | 4,318,716 |
| Market cap | 10.55T |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 52.62 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 60.00 (1.12%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- Business Wire
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
- Business Wire
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors
- Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
© 2024 Yahoo. All rights reserved.